Gapping up
In reaction to earnings/guidance:
- GTLB +18%, SUMO +9.6%, SIG +6.9%, KDP +0.8% (guidance)
Other news:
- VVNT +32% (NRG Energy (NRG) to acquire Vivint for $12 per share or $2.8 bln in an all-cash transaction)
- EDIT +9.4% (safety and efficacy data from the first two patients treated in the RUBY Trial of EDIT-301)
- CENX +3.9% (moving higher after US and EU weigh new tariffs on Chinese steel and aluminum according to Bloomberg)
- ZLAB +3.6% (Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab)
- LILM +3.5% (releases Q3 Business Update)
- LQDA +3.3% (collaborating with Sandoz and Mainbridge Health Partners)
- MNOV +2.8% (Results from Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) Published in The American Journal of Drug and Alcohol Abuse)
- AA +1.7% (moving higher after US and EU weigh new tariffs on Chinese steel and aluminum according to Bloomberg)
- EBS +1.7% (receives FDA acceptance and Priority Review of Supplemental NDA for over-the-counter NARCAN)
- NWSA +1.5% (News Corp. Special Committee provides update on exploration of combination with Fox (FOX))
- BHR +1.4% (reports November 2022 RevPAR)
- GME +1% (begins round of layoffs according to Axios)
Analyst comments:
- PFSI +1.2% (upgraded to Overweight from Equal Weight at Wells Fargo)
- ATVI +0.5% (upgraded to Buy from Hold at Edward Jones)